Tectonic Therapeutic to Participate in Upcoming Investor Conferences
Tectonic Therapeutic Announces Third Quarter 2026 Financial Results and Recent Business Highlights
Tectonic Therapeutic Q3 EPS $(1.08) Beats $(1.33) Estimate
Tectonic Therapeutic, Inc. (TECX) Presents at CureHHT 16thHHT International Scientific Conference - Slideshow
UBS Initiates Coverage On Tectonic Therapeutic with Neutral Rating, Announces Price Target of $26
Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
Tectonic Therapeutic (TECX) Clears Two Trial Hurdles With Cash To Spare
Tectonic Therapeutic: Competitor Data Strengthens The TX45 Bull Case
Wells Fargo Maintains Overweight on Tectonic Therapeutic, Lowers Price Target to $93
Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights
Tectonic Therapeutic Q2 EPS $(1.18) Beats $(1.37) Estimate
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
Raymond James Upgrades Tectonic Therapeutic to Strong Buy, Raises Price Target to $81
TECTONIC THERAPEUTIC INC (NASDAQ:TECX) Q1 Loss Wider Than Expected, Pipeline Progress Provides Key Catalyst
Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights
Tectonic Therapeutic Q1 EPS $(1.34) Misses $(1.18) Estimate
Tectonic Therapeutic (NASDAQ:TECX) Is In A Good Position To Deliver On Growth Plans
Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors
Tectonic Therapeutic: A $1B+ Opportunity Hinges On Upcoming Phase 2
Stifel Initiates Coverage On Tectonic Therapeutic with Buy Rating, Announces Price Target of $75
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.